CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors

Expert Opin Investig Drugs. 2022 Sep;31(9):875-879. doi: 10.1080/13543784.2022.2108588. Epub 2022 Aug 3.

Authors

Christopher Moertel¹, Francisco Martinez-Puerta¹, Grace G Elizabeth Pluhar², Maria Graciela Castro³, Michael Olin¹

Affiliations

¹ Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
² Department of Veterinary Clinical Sciences, University of Minnesota Twin Cities, Minneapolis, MN, USA.
³ Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.

No abstract available

Keywords: CD200; Immune checkpoint; glioblastoma; immunotherapy.

Publication types

Editorial

MeSH terms

Brain
Brain Neoplasms* / pathology
Glioblastoma* / drug therapy
Humans
Immunotherapy

Grants and funding